Grifols, S.A. (NASDAQ:GRFS) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 144.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,002,511 shares of the biotechnology company's stock after purchasing an additional 1,181,959 shares during the period. JPMorgan Chase & Co. owned approximately 0.29% of Grifols worth $17,782,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Tidal Investments LLC acquired a new position in Grifols during the third quarter worth $147,000. Sanctuary Advisors LLC purchased a new position in shares of Grifols in the third quarter valued at approximately $312,000. Geode Capital Management LLC boosted its position in Grifols by 56.1% in the 3rd quarter. Geode Capital Management LLC now owns 110,532 shares of the biotechnology company's stock valued at $982,000 after buying an additional 39,733 shares during the period. Barclays PLC increased its stake in shares of Grifols by 381.2% during the third quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock worth $5,261,000 after buying an additional 469,401 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Grifols during the 3rd quarter worth about $363,000.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded Grifols to a "strong-buy" rating in a research report on Tuesday, October 29th.

Grifols Stock Performance

GRFS traded down $0.31 during trading on Friday, reaching $7.29. The company's stock had a trading volume of 588,626 shares, compared to its average volume of 571,421. The company has a market capitalization of $5.01 billion, a price-to-earnings ratio of 5.98 and a beta of 0.41. The company's fifty day moving average price is $8.08 and its 200-day moving average price is $8.16. Grifols, S.A. has a 52-week low of $5.30 and a 52-week high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.